Ampio Pharmaceuticals (AMPE) Competitors Add Compare Share Share Competitors Stock AnalysisChartCompetitorsInsider TradesSEC FilingsShort InterestTrendsBuy This Stock AMPE vs. NAVB, SCPS, EVLO, CMRA, GNCAQ, GNCA, ARDS, STAB, EFTR, and HSTOShould you be buying Ampio Pharmaceuticals stock or one of its competitors? The main competitors of Ampio Pharmaceuticals include Navidea Biopharmaceuticals (NAVB), Scopus BioPharma (SCPS), Evelo Biosciences (EVLO), Comera Life Sciences (CMRA), Genocea Biosciences (GNCAQ), Genocea Biosciences (GNCA), Aridis Pharmaceuticals (ARDS), Statera Biopharma (STAB), eFFECTOR Therapeutics (EFTR), and Histogen (HSTO). These companies are all part of the "pharmaceutical products" industry. Ampio Pharmaceuticals vs. Its Competitors Navidea Biopharmaceuticals Scopus BioPharma Evelo Biosciences Comera Life Sciences Genocea Biosciences Genocea Biosciences Aridis Pharmaceuticals Statera Biopharma eFFECTOR Therapeutics Histogen Navidea Biopharmaceuticals (NYSE:NAVB) and Ampio Pharmaceuticals (NYSE:AMPE) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, dividends, profitability, media sentiment, valuation, institutional ownership, analyst recommendations and earnings. Do insiders and institutionals believe in NAVB or AMPE? 0.0% of Navidea Biopharmaceuticals shares are owned by institutional investors. Comparatively, 5.7% of Ampio Pharmaceuticals shares are owned by institutional investors. 43.7% of Navidea Biopharmaceuticals shares are owned by insiders. Comparatively, 3.3% of Ampio Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has more risk & volatility, NAVB or AMPE? Navidea Biopharmaceuticals has a beta of 1.75, meaning that its stock price is 75% more volatile than the S&P 500. Comparatively, Ampio Pharmaceuticals has a beta of 4.76, meaning that its stock price is 376% more volatile than the S&P 500. Does the media refer more to NAVB or AMPE? In the previous week, Navidea Biopharmaceuticals' average media sentiment score of 0.00 equaled Ampio Pharmaceuticals'average media sentiment score. Company Overall Sentiment Navidea Biopharmaceuticals Neutral Ampio Pharmaceuticals Neutral Which has stronger earnings & valuation, NAVB or AMPE? Ampio Pharmaceuticals has lower revenue, but higher earnings than Navidea Biopharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNavidea Biopharmaceuticals$8.13K2.46-$15.18MN/AN/AAmpio PharmaceuticalsN/AN/A-$8.63M-$11.01N/A Is NAVB or AMPE more profitable? Company Net Margins Return on Equity Return on Assets Navidea BiopharmaceuticalsN/A N/A N/A Ampio Pharmaceuticals N/A N/A N/A SummaryAmpio Pharmaceuticals beats Navidea Biopharmaceuticals on 3 of the 5 factors compared between the two stocks. Get Ampio Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AMPE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AMPE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AMPE vs. The Competition Export to ExcelMetricAmpio PharmaceuticalsPharmaceutical IndustryMedical SectorNYSE ExchangeMarket CapN/A$838.34M$5.56B$20.64BDividend YieldN/A4.84%5.06%3.72%P/E Ratio0.001.3828.2627.83Price / SalesN/A241.37427.7042.22Price / CashN/A17.6937.1222.32Price / BookN/A6.588.044.57Net Income-$8.63M-$23.83M$3.19B$989.30M Ampio Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AMPEAmpio PharmaceuticalsN/AN/AN/AN/A$0.00N/A0.0020Gap DownNAVBNavidea BiopharmaceuticalsN/A$0.00flatN/AN/A$20K$8.13K0.0010SCPSScopus BioPharmaN/A$0.00flatN/AN/A$13KN/A0.009EVLOEvelo BiosciencesN/A$0.00flatN/AN/A$9KN/A0.00120News CoverageOptions VolumeCMRAComera Life SciencesN/A$0.00flatN/AN/A$6K$1.00M0.002GNCAQGenocea BiosciencesN/AN/AN/AN/A$6KN/A0.0070GNCAGenocea BiosciencesN/AN/AN/AN/A$6K$1.91M0.0070ARDSAridis PharmaceuticalsN/A$0.00flatN/AN/A$5KN/A0.0030News CoverageSTABStatera BiopharmaN/A$0.00flatN/A-83.3%$5KN/A0.0020EFTReFFECTOR Therapeutics0.0758 of 5 stars$0.00-33.3%N/A-99.8%$1KN/A0.0010Gap DownHSTOHistogenN/A$0.00flatN/A-99.9%$1K$19K0.0020 Related Companies and Tools Related Companies Navidea Biopharmaceuticals Competitors Scopus BioPharma Competitors Evelo Biosciences Competitors Comera Life Sciences Competitors Genocea Biosciences Competitors Genocea Biosciences Competitors Aridis Pharmaceuticals Competitors Statera Biopharma Competitors eFFECTOR Therapeutics Competitors Histogen Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:AMPE) was last updated on 7/13/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ampio Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ampio Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
